128 related articles for article (PubMed ID: 32738221)
1. Matrix Metalloproteinases Increase Because of Hypoperfusion in Obstructive Hypertrophic Cardiomyopathy.
Bi X; Yang C; Song Y; Yuan J; Cui J; Hu F; Qiao S
Ann Thorac Surg; 2021 Mar; 111(3):915-922. PubMed ID: 32738221
[TBL] [Abstract][Full Text] [Related]
2. Procollagen type I carboxy-terminal propeptide (PICP) and MMP-2 are potential biomarkers of myocardial fibrosis in patients with hypertrophic cardiomyopathy.
Yang C; Qiao S; Song Y; Liu Y; Tang Y; Deng L; Yuan J; Hu F; Yang W
Cardiovasc Pathol; 2019; 43():107150. PubMed ID: 31639652
[TBL] [Abstract][Full Text] [Related]
3. Serum Matrix Metalloproteinases as Quantitative Biomarkers for Myocardial Fibrosis and Sudden Cardiac Death Risk Stratification in Patients With Hypertrophic Cardiomyopathy.
Münch J; Avanesov M; Bannas P; Säring D; Krämer E; Mearini G; Carrier L; Suling A; Lund G; Patten M
J Card Fail; 2016 Oct; 22(10):845-50. PubMed ID: 27018569
[TBL] [Abstract][Full Text] [Related]
4. Treatment with spironolactone for 24 weeks decreases the level of matrix metalloproteinases and improves cardiac function in patients with chronic heart failure of ischemic etiology.
Li MJ; Huang CX; Okello E; Yanhong T; Mohamed S
Can J Cardiol; 2009 Sep; 25(9):523-6. PubMed ID: 19746242
[TBL] [Abstract][Full Text] [Related]
5. Release of matrix metalloproteinases following alcohol septal ablation in hypertrophic obstructive cardiomyopathy.
Bradham WS; Gunasinghe H; Holder JR; Multani M; Killip D; Anderson M; Meyer D; Spencer WH; Torre-Amione G; Spinale FG
J Am Coll Cardiol; 2002 Dec; 40(12):2165-73. PubMed ID: 12505230
[TBL] [Abstract][Full Text] [Related]
6. Association of Plasma Matrix Metalloproteinase and Tissue Inhibitors of Matrix Metalloproteinase Levels With Adverse Treatment Outcomes Among Patients With Pulmonary Tuberculosis.
Kumar NP; Moideen K; Nancy A; Viswanathan V; Thiruvengadam K; Sivakumar S; Hissar S; Nair D; Banurekha VV; Kornfeld H; Babu S
JAMA Netw Open; 2020 Dec; 3(12):e2027754. PubMed ID: 33258908
[TBL] [Abstract][Full Text] [Related]
7. Quantitative fragmented QRS has a good diagnostic value on myocardial fibrosis in hypertrophic obstructive cardiomyopathy based on clinical-pathological study.
Bi X; Yang C; Song Y; Yuan J; Cui J; Hu F; Qiao S
BMC Cardiovasc Disord; 2020 Jun; 20(1):298. PubMed ID: 32552709
[TBL] [Abstract][Full Text] [Related]
8. Elevated serum markers of collagen degradation in patients with mild to moderate dilated cardiomyopathy.
Schwartzkopff B; Fassbach M; Pelzer B; Brehm M; Strauer BE
Eur J Heart Fail; 2002 Aug; 4(4):439-4. PubMed ID: 12167381
[TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy.
Roldán V; Marín F; Gimeno JR; Ruiz-Espejo F; González J; Feliu E; García-Honrubia A; Saura D; de la Morena G; Valdés M; Vicente V
Am Heart J; 2008 Jul; 156(1):85-91. PubMed ID: 18585501
[TBL] [Abstract][Full Text] [Related]
10. Improvement in collagen metabolism after 12 weeks' cardiac resynchronization therapy in patients with ischaemic cardiomyopathy.
Li M; Zhou Y; Zhou Y; Babu K; Wang Y
J Int Med Res; 2013 Feb; 41(1):200-7. PubMed ID: 23569146
[TBL] [Abstract][Full Text] [Related]
11. Matrix metalloproteinases, tissue inhibitors of metalloproteinases, aminoterminal propeptide of procollagen type III, and hyaluronan in sera and tissue of patients with capsular contracture after augmentation with Trilucent breast implants.
Ulrich D; Lichtenegger F; Eblenkamp M; Repper D; Pallua N
Plast Reconstr Surg; 2004 Jul; 114(1):229-36. PubMed ID: 15220598
[TBL] [Abstract][Full Text] [Related]
12. Myocardial collagen turnover in hypertrophic cardiomyopathy.
Lombardi R; Betocchi S; Losi MA; Tocchetti CG; Aversa M; Miranda M; D'Alessandro G; Cacace A; Ciampi Q; Chiariello M
Circulation; 2003 Sep; 108(12):1455-60. PubMed ID: 12952838
[TBL] [Abstract][Full Text] [Related]
13. Microvascular Rarefaction and Myocardial Fibrosis in Hypertrophic Obstructive Cardiomyopathy.
Tian H; Yang C; Song Y; Wang H; Yuan J; Cui J; Liu S; Hu F; Yang W; Jiang X; Qiao S
Cardiology; 2018; 141(4):202-211. PubMed ID: 30820009
[TBL] [Abstract][Full Text] [Related]
14. Elevated serum markers for collagen synthesis in patients with hypertrophic cardiomyopathy and diastolic dysfunction.
Fassbach M; Schwartzkopff B
Z Kardiol; 2005 May; 94(5):328-35. PubMed ID: 15868361
[TBL] [Abstract][Full Text] [Related]
15. Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure.
Wilson EM; Gunasinghe HR; Coker ML; Sprunger P; Lee-Jackson D; Bozkurt B; Deswal A; Mann DL; Spinale FG
J Card Fail; 2002 Dec; 8(6):390-8. PubMed ID: 12528092
[TBL] [Abstract][Full Text] [Related]
16. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in sera and tissue of patients with Dupuytren's disease.
Ulrich D; Hrynyschyn K; Pallua N
Plast Reconstr Surg; 2003 Oct; 112(5):1279-86. PubMed ID: 14504511
[TBL] [Abstract][Full Text] [Related]
17. Effect of matrix metalloproteinase and their inhibitors on atrial myocardial structural remodeling.
Wang W; Zhang HT; Yang XL
J Cardiovasc Med (Hagerstown); 2013 Apr; 14(4):265-9. PubMed ID: 22929563
[TBL] [Abstract][Full Text] [Related]
18. Plasma monitoring of the myocardial specific tissue inhibitor of metalloproteinase-4 after alcohol septal ablation in hypertrophic obstructive cardiomyopathy.
Stroud RE; Deschamps AM; Lowry AS; Hardin AE; Mukherjee R; Lindsey ML; Ramamoorthy S; Zile MR; Spencer WH; Spinale FG
J Card Fail; 2005 Mar; 11(2):124-30. PubMed ID: 15732032
[TBL] [Abstract][Full Text] [Related]
19. Role of matrix metalloproteinases and their tissue inhibitors as potential biomarkers of left ventricular remodelling in the athlete's heart.
Vianello A; Caponi L; Franzoni F; Galetta F; Rossi M; Taddei M; Malvaldi G; Pietrini P; Santoro G
Clin Sci (Lond); 2009 Jul; 117(4):157-64. PubMed ID: 19196241
[TBL] [Abstract][Full Text] [Related]
20. Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer.
Ylisirniö S; Höyhtyä M; Mäkitaro R; Pääakkö P; Risteli J; Kinnula VL; Turpeenniemi-Hujanen T; Jukkola A
Clin Cancer Res; 2001 Jun; 7(6):1633-7. PubMed ID: 11410500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
